SAGE Therapeutics (NASDAQ:SAGE) had its price target lowered by Royal Bank of Canada from $190.00 to $100.00 in a research note published on Friday morning, Briefing.com Automated Import reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also weighed in on the company. Leerink Swann upgraded SAGE Therapeutics from an underperform rating to a market perform rating and set a $63.00 price target for the company in a research report on Friday. BMO Capital Markets restated an outperform rating and set a $92.00 price objective on shares of SAGE Therapeutics in a report on Friday. Svb Leerink raised shares of SAGE Therapeutics from an underperform rating to a market perform rating in a research note on Friday. ValuEngine upgraded shares of SAGE Therapeutics from a buy rating to a strong-buy rating in a report on Thursday. Finally, Guggenheim decreased their target price on shares of SAGE Therapeutics from $200.00 to $110.00 and set a buy rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $128.81.
SAGE opened at $64.46 on Friday. The firm has a market cap of $3.34 billion, a PE ratio of -7.98 and a beta of 2.52. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $142.30 and a 200-day simple moving average of $160.81. SAGE Therapeutics has a fifty-two week low of $56.50 and a fifty-two week high of $193.56.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Amundi Pioneer Asset Management Inc. increased its stake in SAGE Therapeutics by 40.7% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock valued at $21,704,000 after buying an additional 39,447 shares during the period. Commonwealth Equity Services LLC lifted its position in SAGE Therapeutics by 4.5% in the 2nd quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 77 shares in the last quarter. Creative Planning boosted its stake in shares of SAGE Therapeutics by 13.0% during the 2nd quarter. Creative Planning now owns 2,563 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 294 shares during the period. Janney Capital Management LLC boosted its stake in shares of SAGE Therapeutics by 18.2% during the 2nd quarter. Janney Capital Management LLC now owns 4,387 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 675 shares during the period. Finally, Janney Montgomery Scott LLC grew its holdings in shares of SAGE Therapeutics by 5.0% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $834,000 after acquiring an additional 219 shares in the last quarter.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Featured Article: Book Value Per Share in Stock Trading
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.